HISTALIM
9.3.2017 09:02:37 CET | Business Wire | Press release
In 2016 HISTALIM observed an increasing demand from its customers and partners for multiplex imagery. The company leads several development programs and is involved in numerous clinical trials in the field of cancer immuno therapies. In this particular area HISTALIM performs studies which aim at characterizing the tumor microenvironment and its interaction with immune cells.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170309005076/en/
The extraction of quantitative data on a high number of markers despite the limited availability of biological material represents a major stake in this kind of study. Another challenge deals with the analysis of the interaction between several markers involved in immune mechanisms on one single slide.
Histalim chose to bring enhanced precision and efficacy in biopsies and tissue samples by utilizing the Vectra Polaris technology. The Vectra Polaris system is the first slide scanner which enables multiplex analysis on histopathological markers.
Dr. Laurent LAGUERRE (HISTALIM), who led the discussions with PerkinElmer, said: “We have been impressed by this technology combining multiplex imagery with slide scanning. This is the most advanced research solution for digital pathology on IHC multiplex labelling. ”
With slides containing up to 7 colors, the histopathologists collaborating with Histalim will then be able to bring all their expertise, whether they are located in house or at the client’s site.
Mr. Terry Lo, General Manager, Quantitative Pathology, PerkinElmer, declared: “We are very proud of this agreement which makes HISTALIM our first European customer. This relationship represents a huge accelerator for the development of Vectra Polaris technology in Europe since HISTALIM is engaged in many clinical trials in immuno-oncology. ”
The Vectra Polaris system was officially launched internationally on 26th of January 2017.
About HISTALIM :
HISTALIM is a European leading company in
the field of histopathology services, and tissue based assays. Ranging
from neurosciences to toxicity assessment, from the characterization of
therapeutic antibodies to the evaluation of implantable medical
devices..., the company focus on accompanying each client to provide
each of them with a perfectly controlled service.
The company knows
an important growth due to its strategic position in the development of
immuno-oncology and biotherapies as a service provider.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170309005076/en/
Contact:
HISTALIM
Press contact:
Jean-Philippe COTON,
+33619646737
contact@histalim.com
https://www.linkedin.com/company/histalim
https://twitter.com/HISTALIM
https://www.youtube.com/channel/UC7-k5ev53LRMHqXCawF-fMg
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM achieves milestone in quantum error correction, enabling fault-tolerant computing in the near-term23.6.2026 16:41:00 CEST | Press release
New research introduces a family of error-correcting codes that reduce qubit overhead by up to 1,000 times compared to today’s leading approach — without requiring any new hardware. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced a significant achievement in quantum error correction, using directional tile codes, marking a major step toward practical, large-scale fault-tolerant quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623243333/en/ IQM achieves milestone in quantum error correction, enabling fault-tolerant computing in the near-term The research, available on arXiv, and co-authored by IQM researchers and collaborators at Freie Universität Berlin, the University of Edinburgh, and Johannes Gutenberg-Universität Mainz, introduces ‘directional tile codes’, a new family of quantum error-correcting codes that resolves one of the central tensions in quantum
NetApp Enhances Support for AI Workloads at Massive Scale23.6.2026 16:00:00 CEST | Press release
StorageGRID 12.1 delivers up to 12TB/s throughput and massive scale for AI workloads NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced the release of StorageGRID 12.1, designed to help customers scale AI and other modern workloads with a federated global namespace. The new capabilities improve how data is accessed, processed, and managed across distributed environments to support AI data pipelines, data lakes, and modern object-based applications. Organizations are contending with rapid growth in unstructured data to serve AI workloads while also managing that data across increasingly distributed hybrid environments. In its Object Storage Solutions Landscape, Q1 2026 report, Forrester notes that the rise of generative AI has pushed object storage further into an AI‑optimized data platform beyond its historical uses supporting enterprise data strategies with scalable, durable storage for unstructured data, media, and backups. The updates to NetApp Stor
GigaDevice and Qt Group Announce Global Partnership to Advance the Embedded GUI Ecosystem23.6.2026 16:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, has officially entered a strategic partnership with Qt Group, a global leader in software design, development, and quality assurance solutions. Leveraging the GD32H7 high-performance MCU series, the two companies will collaborate to optimize and enhance embedded GUI solutions, enabling developers to create more intuitive, visually rich, and responsive user experiences. This collaboration further expands GigaDevice’s ecosystem strategy in advanced human-machine interface (HMI) and establishes a solid foundation for future innovation across smart industry solutions, energy storage systems, smart home devices, and consumer electronics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623351273/en/ GigaDevice and Qt Group Announce Global Partnership to Advance the Embedded GUI Ecosystem As IoT,
Otonal Launches Localization Service to Adapt English Podcasts and Audio Ads for the Japanese Market23.6.2026 16:00:00 CEST | Press release
Otonal Inc., a Tokyo-based digital audio advertising and podcast technology company, has officially launched a specialized audio localization service designed to help global brands and media companies adapt their English-language podcasts and audio advertisements for the Japanese market. Audio Ad Localization https://otonal.co.jp/en/audioad-localization/ Podcast Localization https://otonal.co.jp/en/podcast-localization/ While many translation vendors focus on text-based, one-size-fits-all translation, Otonal’s service addresses the distinct challenges of audio-first localization. The service goes beyond standard translation by rebuilding scripts for spoken Japanese, ensuring precise 15- and 30-second ad timings, adapting the content to local cultural context, and casting native Japanese voice talent suited to the content and delivery environment to maintain brand authority and tone. Japan ranks among the world's leading economies and is one of Asia’s largest advertising markets, making
Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies23.6.2026 15:30:00 CEST | Press release
Saturnus Bio is a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet needThe collaboration will augment Merck’s efforts to pursue precision medicine-defined indicationsNot intended for Canada-, UK- or US-based media Merck, a leading global science and technology company, today announced a strategic research-stage collaboration with Saturnus Bio, a Versant Ventures-founded biotech, aimed at establishing a foundational portfolio in the promising field of rare genetic cardiomyopathies. This partnership aligns with the company’s commitment to address significant unmet medical needs in rare populations through targeted treatments. “Through our partnership with Saturnus Bio, we aim to fast track the development of innovative therapies for genetic cardiomyopathies through precision cardiology, targeting the rare population impacted by these conditions,” said David Weinreich, MD, Head of Resea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom